CN109369491A - A new class of ezetimibe derivative and preparation method thereof - Google Patents
A new class of ezetimibe derivative and preparation method thereof Download PDFInfo
- Publication number
- CN109369491A CN109369491A CN201811501676.3A CN201811501676A CN109369491A CN 109369491 A CN109369491 A CN 109369491A CN 201811501676 A CN201811501676 A CN 201811501676A CN 109369491 A CN109369491 A CN 109369491A
- Authority
- CN
- China
- Prior art keywords
- ezetimibe
- preparation
- new class
- dissolved
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a new class of ezetimibe derivatives, which is characterized in that its structural formula is shown in formula I:
Description
Technical field
The present invention relates to field of pharmaceutical chemistry technology more particularly to a new class of ezetimibe derivative and its preparation sides
Method.
Background technique
Ezetimibe is a kind of cholesterol absorption inhibitor/NPC1L1 inhibitor, can be used as homozygous sub-family diet control
Adjuvant treatment in addition can be united and applied in treatment primary (heterozygosis individually or with HMG-CoA reductase inhibitor (Statins)
Sub-family or non-familial) hypercholesterolemia, can reduce total cholesterol (TC), low density lipoprotein cholesterol (LDL-C),
Apolipoprotein；With Statins use in conjunction, complementary therapy (such as LDL-C blood plasma separation displacement of other lipid-lowering therapies can be used as
Method), or when other lipid-lowering therapies are invalid for reducing the TC of HoFH patient and LDL-C level；Other than diet control
Adjuvant treatment, it is horizontal for reducing the sitosterol and phytosterol of homozygote familial Sitosterolemia patient.
Ezetimibe lipophilicity is strong, Determination of oil-water partition coefficient logP=4.5, thus solubility in water it is extremely low (23 DEG C,
0.012mg/ml), these factors affect pharmaceutical dosage form design and existing dosage form bioavilability it is lower (35-65%).Compared with
The solubility of difference causes therapeutic effect to decline with dissolution rate, and very big obstacle is caused to the clinical expansion of drug.Therefore, pass through knot
Structure modification, which improves ezetimibe water solubility, has very high researching value.
Summary of the invention
It is an object of the invention to disclose a new class of ezetimibe derivative, the water solubility of ezetimibe is improved, just
In the clinical expansion of drug.
To achieve the above object, the present invention provides a new class of ezetimibe derivative, structural formula is shown in formula I:
Wherein, R is selected from following table:
The present invention also provides the preparation method of a new class of ezetimibe derivative (Formulas I structural compounds), this method
It is starting with (4S) -3- [(5S) -5- (4- fluorophenyl) -5- hydroxypentanoyl base] -4- phenyl -1,3- oxaza pentane -2- ketone
Object, etherificate, after TBDMSCl protection, 4- [[(4- fluorophenyl) imino group] methyl] coupling of-phenol, cyclization, acid with benzyl protection
Change, hydrogenation, most afterwards through being recrystallized to give target product.
Further, compound A10 is made according to the method described above, structural formula is as follows:
Further, compound A10's step 1: by (4S) -3- [(5S) -5- (4- fluorophenyl) -5- hydroxyl is prepared
Valeryl] -4- phenyl -1,3- oxaza pentane -2- ketone is dissolved in DMF, sequentially adds potassium carbonate and N- hydroxyethyl morpholine, it feeds
After be stirred at room temperature 2h, TLC judgement reaction terminates, and reaction solution is poured into ice water, is filtered, filter cake is dried in vacuo white solid
Body, i.e. intermediate A 10-1.
Further, compound A10's step 2: by the 4- [[(4- fluorophenyl) imino group] of benzyl protection is prepared
Methyl]-phenol is dissolved in DMF, sequentially adds potassium carbonate and benzyl chloride, and 2h is stirred at room temperature after charging, and TLC judgement reaction terminates,
Reaction solution is poured into ice water, is filtered, filter cake is dried in vacuo to obtain white solid, i.e. intermediate A 10-2.
Further, compound A10's step 3: first by TiCl is prepared4It is dissolved in methylene chloride, 0 DEG C of dropwise addition Ti (O-
i-Pr)4, insulation reaction 30min, obtained TiCl4+Ti(O-i-Pr)4Mixed solution；
Intermediate A 10-1 and intermediate A 10-2 is dissolved in methylene chloride, and -15 DEG C are successively added dropwise DIPEA and TiCl4+Ti(O-
i-Pr)4Then glacial acetic acid is added dropwise, and ice bath is cooling, and reaction solution is poured into 7% winestone in mixed solution, the 2h that is added dropwise that the reaction was continued
Aqueous acid stirs 1h, warms naturally to room temperature, and 20% solution of sodium bisulfite is added, and continues to stir 2h, and organic layer separates,
Washing, anhydrous sodium sulfate is dry, filters, and filtrate builds industry concentration, and methanol mashing obtains white solid, i.e. intermediate A 10-3.
Further, compound A10's step 4: intermediate A 10-3 is dissolved in methylene chloride is prepared, is sequentially added
2h is stirred at room temperature in BSA and TBAF, and TLC judgement reaction end adjusts PH to 7 with acetic acid, is concentrated under reduced pressure, after ethyl acetate extraction,
Ice water washing, anhydrous sodium sulfate is dry, filters, and filtrate is concentrated to give crude product, i.e. intermediate A 10-4.
Further, compound A10's step 5: intermediate A 10-4 is dissolved in ethyl acetate is prepared, is added 10%
Pd/C, overnight, TLC judgement reaction terminates the reaction of room temperature atmospheric hydrogenation, filters, and filtrate decompression concentration, residue recrystallized from acetonitrile obtains
White crystal, i.e. compound A10.
Compared with prior art, the beneficial effects of the present invention are: improving the water solubility of ezetimibe, it is more advantageous to drug
Clinical use.
Specific embodiment
Below with reference to each embodiment, the present invention is described in detail, but it should be stated that, these embodiments are simultaneously
Non- limitation of the present invention, those of ordinary skill in the art are according to these embodiments in made function, method or structure
Equivalent transformation or substitution, all belong to the scope of protection of the present invention within.
The present invention provides a new class of ezetimibe derivative, structural formula is shown in formula I:
Wherein, R is selected from following table:
The present invention also provides the preparation method of a new class of ezetimibe derivative (Formulas I structural compounds), this method
It is starting with (4S) -3- [(5S) -5- (4- fluorophenyl) -5- hydroxypentanoyl base] -4- phenyl -1,3- oxaza pentane -2- ketone
Object, etherificate, after TBDMSCl protection, 4- [[(4- fluorophenyl) imino group] methyl] coupling of-phenol, cyclization, acid with benzyl protection
Change, hydrogenation, most afterwards through being recrystallized to give target product.
Embodiment one:
Present embodiment discloses a kind of compound A1 obtained according to the method described above, structural formula is as follows:
The preparation method of compound A1:
1.1) synthesis of intermediate A 1-1
Formula EZ-1 is (4S) -3- [(5S) -5- (4- fluorophenyl) -5- hydroxyl -1- oxopentyl] -4- phenyl -2- oxazolidine
The structural formula of ketone.
(4S) -3- [(5S) -5- (4- fluorophenyl) -5- hydroxyl -1- oxopentyl] -4- phenyl -2- oxazolidone (35.7g,
It 0.1mol) is dissolved in 20mlDMF, potassium carbonate (27.6g, 0.2mol) and ethylene glycol (60g, 1mol) are sequentially added, after charging
2h is stirred at room temperature, TLC judgement reaction terminates, reaction solution is poured into ice water, is filtered, filter cake is dried in vacuo to obtain white solid 36.3g.
1.2) synthesis of intermediate A 1-2
By intermediate A 1-1 (41.7g, 0.1mol), imidazoles (10.2g, 0.15mol) is dissolved in 50mlDMF, is added portionwise
TBDMSCl (18.1g, 0.12mol), charging, which finishes, is stirred at room temperature reaction 1h, ethyl acetate dilution, and ice water extraction is gone out, liquid separation, water layer
It is washed 2 times with ethyl acetate, merges organic layer, it is dry with anhydrous sodium sulfate after washing, it filters, filtrate concentration obtains grease
45.0g。
1.3) synthesis of intermediate A 1-3
Formula EZ-2 is the structural formula of 4- [[(4- fluorophenyl) imino group] methyl]-phenol.
4- [[(4- fluorophenyl) imino group] methyl]-phenol (21.5g, 0.1mol) is dissolved in 20mlDMF, sequentially adds carbonic acid
2h is stirred at room temperature in potassium (27.6g, 0.2mol) and benzyl chloride (12.6g, 0.1mol) after charging, TLC judgement reaction terminates, will
Reaction solution pours into ice water, filters, and filter cake is dried in vacuo to obtain white solid 20.3g.
1.4) synthesis of intermediate A 1-4
TiCl4+Ti(O-i-Pr)4The preparation of mixed solution: by TiCl4(21.3g, 0.112mol) is dissolved in 100ml dichloromethane
Alkane, 0 DEG C of dropwise addition Ti (O-i-Pr)4(10.6g, 0037mol), insulation reaction 30min.Intermediate A 1-2 (53.4g, 0.1mol) and
Intermediate A 1-3 (61.4g, 0.2mol) is dissolved in 250ml methylene chloride, -15 DEG C be successively added dropwise DIPEA (25.8g, 0.2mol) and
TiCl4+Ti(O-i-Pr)4Then glacial acetic acid (30g, 0.5mol) is added dropwise, ice bath is cold in mixed solution, the 2h that is added dropwise that the reaction was continued
But, reaction solution is poured into 7% aqueous tartaric acid solution, stirs 1h, warm naturally to room temperature, 20% solution of sodium bisulfite is added
100ml continues to stir 2h, and organic layer separation, washing, anhydrous sodium sulfate is dry, filters, and filtrate builds industry concentration, and 50ml methanol is beaten
Slurry, white solid 62.1g.
1.5) synthesis of intermediate A 1-5
Intermediate A 1-4 (8.4g, 10mmol) is dissolved in 80ml methylene chloride, sequentially add BSA (4.1g, 20mmol) and
TBAF (261mg, 1mmol), is stirred at room temperature 2h, and TLC judgement reaction end adjusts PH to 7 with acetic acid, is concentrated under reduced pressure, ethyl acetate
After extraction, ice water washing, anhydrous sodium sulfate is dry, filters, and filtrate is concentrated to give crude product 5.9g.
1.6) synthesis of intermediate A 1-6
Intermediate A 1-5 (6.6g, 10mmol) is dissolved in 10ml isopropanol, 2N concentrated sulfuric acid 2ml is added, 2h is stirred at room temperature, instead
It answers liquid to pour into 80ml ice water, filters, the white solid 4.9g of filter cake drying.
1.7) synthesis of compound A1
Intermediate A 1-6 (5.43g, 10mmol) is dissolved in 20ml ethyl acetate, 10%Pd/C250mg, room temperature normal pressure is added
Hydrogenation reaction is stayed overnight, and TLC judgement reaction terminates, and filters, and filtrate decompression concentration, residue recrystallized from acetonitrile obtains white crystal 4.1g.
Embodiment two
Present embodiment discloses a kind of compound A10 obtained according to the method described above, structural formula is as follows:
2.1) synthesis of intermediate A 10-1
Formula EZ-1 is (4S) -3- [(5S) -5- (4- fluorophenyl) -5- hydroxyl -1- oxopentyl] -4- phenyl -2- oxazolidine
The structural formula of ketone.
(4S) -3- [(5S) -5- (4- fluorophenyl) -5- hydroxyl -1- oxopentyl] -4- phenyl -2- oxazolidone (35.7g,
It 0.1mol) is dissolved in 20mlDMF, sequentially adds potassium carbonate (27.6g, 0.2mol) and N- hydroxyethyl morpholine (114g, 1mol), is fed
After be stirred at room temperature 2h, TLC judgement reaction terminates, and reaction solution is poured into ice water, is filtered, filter cake is dried in vacuo to obtain white solid
37.5g。
2.2) synthesis of intermediate A 10-2
Formula EZ-2 is the structural formula of 4- [[(4- fluorophenyl) imino group] methyl]-phenol.
4- [[(4- fluorophenyl) imino group] methyl]-phenol (21.5g, 0.1mol) is dissolved in 20mlDMF, sequentially adds carbonic acid
2h is stirred at room temperature in potassium (27.6g, 0.2mol) and benzyl chloride (12.6g, 0.1mol) after charging, TLC judgement reaction terminates, will
Reaction solution pours into ice water, filters, and filter cake is dried in vacuo to obtain white solid 20.3g.
2.3) synthesis of intermediate A 10-3
TiCl4+Ti(O-i-Pr)4The preparation of mixed solution: by TiCl4(21.3g, 0.112mol) is dissolved in 100ml dichloromethane
Alkane, 0 DEG C of dropwise addition Ti (O-i-Pr)4(10.6g, 0037mol), insulation reaction 30min.
Intermediate A 10-1 (47.1g, 0.1mol) and intermediate A 10-2 (61.4g, 0.2mol) are dissolved in 250ml dichloromethane
Alkane, -15 DEG C are successively added dropwise DIPEA (25.8g, 0.2mol) and TiCl4+Ti(O-i-Pr)4It is anti-that continuation is added dropwise in mixed solution
2h to be answered, glacial acetic acid (30g, 0.5mol) then is added dropwise, ice bath is cooling, and reaction solution is poured into 7% aqueous tartaric acid solution, stirs 1h,
Room temperature is warmed naturally to, 20% solution of sodium bisulfite 100ml is added, continues to stir 2h, organic layer separation, washing, anhydrous sulphur
Sour sodium is dry, filters, filtrate concentration, the mashing of 50ml methanol, white solid 60.2g.
2.4) synthesis of intermediate A 10-4
Intermediate A 10-3 (7.7g, 10mmol) is dissolved in 80ml methylene chloride, sequentially add BSA (4.1g, 20mmol) and
TBAF (261mg, 1mmol), is stirred at room temperature 2h, and TLC judgement reaction end adjusts PH to 7 with acetic acid, is concentrated under reduced pressure, ethyl acetate
After extraction, ice water washing, anhydrous sodium sulfate is dry, filters, and filtrate is concentrated to give crude product 5.3g.
2.5) synthesis of compound A10
Intermediate A 10-4 (4.99g, 10mmol) is dissolved in 20ml ethyl acetate, 10%Pd/C250mg is added, room temperature is normal
Hydrogenation reaction is pressed to stay overnight, TLC judgement reaction terminates, and filters, and filtrate decompression concentration, residue recrystallized from acetonitrile obtains white crystal
3.89g。
It is as follows that the solubility of ezetimibe and ezetimibe derivative A1 to A10 detect table:
As seen from the above table, the ezetimibe derivative synthesized according to preparation method of the present invention, solubility ratio is according to replacing
Rice shellfish is much higher, wherein the water solubility with the ezetimibe derivative of A7 and A8 is more preferable.
The series of detailed descriptions listed above only for feasible embodiment of the invention specifically
Protection scope bright, that they are not intended to limit the invention, it is all without departing from equivalent implementations made by technical spirit of the present invention
Or change should all be included in the protection scope of the present invention.
In addition, it should be understood that although this specification is described in terms of embodiments, but not each embodiment is only wrapped
Containing an independent technical solution, this description of the specification is merely for the sake of clarity, and those skilled in the art should
It considers the specification as a whole, the technical solutions in the various embodiments may also be suitably combined, forms those skilled in the art
The other embodiments being understood that.
Claims (8)
1. a new class of ezetimibe derivative, which is characterized in that its structural formula is shown in formula I:
Wherein, R is selected from following table:
2. the preparation method of a new class of ezetimibe derivative, which is characterized in that this method is with (4S) -3- [(5S) -5- (4-
Fluorophenyl) -5- hydroxypentanoyl base] -4- phenyl -1,3- oxaza pentane -2- ketone be starting material, etherificate, TBDMSCl protection
Afterwards, it with the 4- of benzyl protection [[(4- fluorophenyl) imino group] methyl] coupling of-phenol, cyclization, acidification, hydrogenation, is most tied again afterwards
Crystalline substance obtains target product.
3. the preparation method of a new class of ezetimibe derivative according to claim 2, which is characterized in that according to above-mentioned
Compound A10 is made in method, and structural formula is as follows:
4. the preparation method of a new class of ezetimibe derivative according to claim 3, which is characterized in that described in preparation
Compound A10's step 1: by (4S) -3- [(5S) -5- (4- fluorophenyl) -5- hydroxypentanoyl base] -4- phenyl -1,3- oxygen azepine
Pentamethylene -2- ketone is dissolved in DMF, sequentially adds potassium carbonate and N- hydroxyethyl morpholine, and 2h, TLC judgement are stirred at room temperature after charging
Reaction terminates, and reaction solution is poured into ice water, filters, and filter cake is dried in vacuo to obtain white solid, i.e. intermediate A 10-1.
5. the preparation method of a new class of ezetimibe derivative according to claim 4, which is characterized in that described in preparation
Compound A10's step 2: 4- [[(4- fluorophenyl) imino group] methyl]-phenol of benzyl protection is dissolved in DMF, sequentially adds
Potassium carbonate and benzyl chloride, are stirred at room temperature 2h after charging, TLC judgement reaction terminates, reaction solution is poured into ice water, is filtered, filter cake
It is dried in vacuo to obtain white solid, i.e. intermediate A 10-2.
6. the preparation method of a new class of ezetimibe derivative according to claim 5, which is characterized in that described in preparation
Compound A10's step 3: first by TiCl4It is dissolved in methylene chloride, 0 DEG C of dropwise addition Ti (O-i-Pr)4, insulation reaction 30min, be made
TiCl4+Ti(O-i-Pr)4Mixed solution；
Intermediate A 10-1 and intermediate A 10-2 is dissolved in methylene chloride, and -15 DEG C are successively added dropwise DIPEA and TiCl4+Ti(O-i-Pr)4
Then glacial acetic acid is added dropwise, and ice bath is cooling, and it is water-soluble that reaction solution is poured into 7% tartaric acid in mixed solution, the 2h that is added dropwise that the reaction was continued
Liquid stirs 1h, warms naturally to room temperature, and 20% solution of sodium bisulfite is added, and continues to stir 2h, organic layer separation, washing, nothing
Aqueous sodium persulfate is dry, filters, and filtrate builds industry concentration, and methanol mashing obtains white solid, i.e. intermediate A 10-3.
7. the preparation method of a new class of ezetimibe derivative according to claim 6, which is characterized in that described in preparation
Compound A10's step 4: intermediate A 10-3 is dissolved in methylene chloride, sequentially adds BSA and TBAF, 2h, TLC is stirred at room temperature
Judgement reaction end adjusts PH to 7 with acetic acid, is concentrated under reduced pressure, and after ethyl acetate extraction, ice water washing, anhydrous sodium sulfate is dry,
It filters, filtrate is concentrated to give crude product, i.e. intermediate A 10-4.
8. the preparation method of a new class of ezetimibe derivative according to claim 7, which is characterized in that described in preparation
Compound A10's step 5: intermediate A 10-4 is dissolved in ethyl acetate, is added 10%Pd/C, room temperature atmospheric hydrogenation reacted
Night, TLC judgement reaction terminate, filter, and filtrate decompression concentration, residue recrystallized from acetonitrile obtains white crystal, i.e. compound A10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811501676.3A CN109369491A (en) | 2018-12-10 | 2018-12-10 | A new class of ezetimibe derivative and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811501676.3A CN109369491A (en) | 2018-12-10 | 2018-12-10 | A new class of ezetimibe derivative and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109369491A true CN109369491A (en) | 2019-02-22 |
Family
ID=65373946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811501676.3A Withdrawn CN109369491A (en) | 2018-12-10 | 2018-12-10 | A new class of ezetimibe derivative and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109369491A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004005247A1 (en) * | 2002-07-05 | 2004-01-15 | Astrazeneca Ab | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
| US20050171080A1 (en) * | 2003-12-23 | 2005-08-04 | Dr. Reddy's Laboratories, Inc. | Polymorphs of ezetimibe and process for preparation thereof |
| CN1870988A (en) * | 2003-10-30 | 2006-11-29 | 默克公司 | 2-azetidinones as anti-hypercholesterolemic agents |
| CN103254107A (en) * | 2013-05-09 | 2013-08-21 | 东华大学 | Ezetimibe analogue and preparation method thereof |
| CN104513187A (en) * | 2015-01-09 | 2015-04-15 | 安润医药科技（苏州）有限公司 | Ezetimibe synthesis method and Ezetimibe intermediate synthesis method |
| CN104892537A (en) * | 2015-05-15 | 2015-09-09 | 江西施美制药有限公司 | Ezetimibe intermediate and synthesis method of ezetimibe |
-
2018
- 2018-12-10 CN CN201811501676.3A patent/CN109369491A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004005247A1 (en) * | 2002-07-05 | 2004-01-15 | Astrazeneca Ab | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
| CN1870988A (en) * | 2003-10-30 | 2006-11-29 | 默克公司 | 2-azetidinones as anti-hypercholesterolemic agents |
| US20050171080A1 (en) * | 2003-12-23 | 2005-08-04 | Dr. Reddy's Laboratories, Inc. | Polymorphs of ezetimibe and process for preparation thereof |
| CN103254107A (en) * | 2013-05-09 | 2013-08-21 | 东华大学 | Ezetimibe analogue and preparation method thereof |
| CN104513187A (en) * | 2015-01-09 | 2015-04-15 | 安润医药科技（苏州）有限公司 | Ezetimibe synthesis method and Ezetimibe intermediate synthesis method |
| CN104892537A (en) * | 2015-05-15 | 2015-09-09 | 江西施美制药有限公司 | Ezetimibe intermediate and synthesis method of ezetimibe |
Non-Patent Citations (5)
| Title |
|---|
| AMIT SINGH等: "Lipase catalyzed kinetic resolution for the production of (S)-3-[5-(4-fluoro-phenyl)-5-hydroxy-pentanoyl]-4-phenyl-oxazolidin-2-one: An intermediate for the synthesis of ezetimibe", 《JOURNAL OF MOLECULAR CATALYSIS B: ENZYMATIC》 * |
| 刘庆俭: "《有机化学 上》", 30 November 2018, 同济大学出版社 * |
| 夏彬: "降血脂药依折麦布衍生物的合成研究", 《贵州医科大学硕士学位论文》 * |
| 荣国斌等: "《高等有机化学》", 31 October 2007 * |
| 邢其毅等: "《基础有机化学 上》", 30 November 1993 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1996019450A1 (en) | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents | |
| EP1942905A2 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| KR20060056352A (en) | Angiotensin ii receptor blocker derivatives | |
| BG61118B2 (en) | Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof | |
| CN111170855A (en) | Compound and method for synthesizing 8-hydroxy-2, 2,14, 14-tetramethylpentadecanedioic acid by using same | |
| EA030383B1 (en) | Bicyclically substituted uracils, processes for preparation thereof, use thereof, medicament and method for treatment using same | |
| RU2109743C1 (en) | Galantamine derivatives and pharmaceutical composition | |
| CN103333134B (en) | 2-(3-cyano group-4-alkoxyl group) phenyl-4-substituted thiazole-5-formic acid compound, composition and method of making the same and purposes | |
| TWI597273B (en) | Nitrogen-containing heterocyclic compound | |
| NO317395B1 (en) | Alpha-aryl- or heteroaryl-substituted amide ester ACAT inhibitors | |
| SK287644B6 (en) | Form C of crystalline N-(trans-4-isopropylcyclohexylcarbonyl)-D- phenylalanine and process for preparing thereof | |
| CN109369491A (en) | A new class of ezetimibe derivative and preparation method thereof | |
| CN106749045A (en) | A kind of new D amino acid oxidase inhibitors and its preparation method and application | |
| CN109293547A (en) | A new class of Ezetimibe derivative and preparation method thereof | |
| CN102249937A (en) | Preparation method of 1-(S)-4, 5-dimethyamino-1-methylaminomethyl-benzocyclobutane | |
| US6159976A (en) | Polymorph of zopolrestat monohydrate | |
| CN108349872A (en) | The synthesis of terphenyl compounds | |
| CN109293548A (en) | A kind of preparation method of high-quality HMG-CoA reductase inhibitor Atorvastatin calcium | |
| CN109384700A (en) | A new class of Ezetimibe analog and preparation method thereof | |
| BE897208A (en) | CARBOSTYRYLE COMPOUNDS | |
| CN106279018B (en) | Beta 2-receptor excitant and its preparation method and application | |
| CN105198786A (en) | Aryl-substituted amide compound, preparing method thereof, medicine composition comprising same, and application thereof | |
| WO1993018030A1 (en) | Benzimidazole derivatives as angiotensin ii antagonists | |
| CN112390816B (en) | Preparation method of oxazepine compound | |
| CN111233661A (en) | Compound for targeted ubiquitination degradation of ERR α protein and medicinal composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190222 |